Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy
oleh: Zhongbo Hu, Kristen A. VanHeyst, Jignesh Dalal, Lisa Hackney
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-03-01 |
Deskripsi
Abstract DS‐ALL has a higher rate of relapse and treatment‐related mortality. The newer immunotherapies are potentially better options. Relapsed ALL with positive MRD has a poor prognosis. Transient long‐term remission after ALL relapse due to partial chemotherapy combined severe infection is rare.